Vaccination in newborns and infants
AssigneeCureVac AG
InventorsKarl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
Life of this patent
Estimating the term…
Abstract
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
Claims15
A method for stimulating an immune response in an infant subject comprising, administering an effective amount of a composition comprising a purified mRNA encoding an influenza hemagglutinin (HA) virus antigen to the infant subject thereby stimulating an antigen-specific Th1 immune response in the subject, said infant subject being no more than 2 years of age, wherein the composition is administered via injection.
Dependencies are inferred from the claim text.